QSAR - Neurodegenerative Disorders 2004

> Neurodegenerative Disorders 2004
> 31st March & 1st April 2004 Marriott Kensington Hotel, London
>
> Neurodegenerative therapies will be one of the
> defining growth areas over the next 10-20 years:
> * With an aging population, cases of alzheimer's, parkinson's and
> similar diseases will increase exponentially
> * Also, as new treatments are developed, more cases will become
> treatable,and for longer..
> * Both these factors will lead to an an economic windfall for
> pharmaceutical/biotech companies that embrace this sector.
>
> Full analysis of current market AND future developments:
> * Case studies of current drug treatments (eg. Mirapex, Rilutek)
> * Pipeline/Early market drugs - Antegren, Axura.
> * The impact/viability of gene therapy/stem cell treatments.
> * Other novel treatments - eg. surgical implantation
> * Plus much more analysis...FULL AGENDA BELOW.
>
> Network with key speakers at Neuro 2004, who will include:
>
> Dr. Stephen Donoghue, VP of Clinical Development, Europe, Elan
> Dr. Beth Hoffman, Head Neuroscience Discovery Research, Eli Lilly
> Dr. Hans Basun, Senior Clinical Research Physician, AstraZeneca
> Dr. Donna Barten, Senior Research Investigator, Neuroscience Drug Discovery, Bristol-Myers Squibb
> Dr. Michel Dib, Medical Director for Internal Medicines Department, Aventis
> Dr Chriso Babatsikos, International Product Manager Pramipexole, Boehringer-Ingelheim
> Dr. Gerald Yakatan, President and CEO, Avanir Pharmaceuticals
> Prof. Alan Kingsman, Chief Executive Officer, Oxford BioMedica
> Eric Kmiec, Chief Scientific Officer, NaPro Bio Therapeutics
> Dr. Christian Gilles, Director, R&D & Head, CNS Ageing Research, Forenap
> Friedhelm Klingenburg, Senior VP for Corporate Development, Merz Pharmaceuticals
> Dr. Eti Yoles, Vice President Product Research and Development, Proneuron Biotechnologies
> Helen Hodges, Head of Functional Assessment Group, ReNeuron
> Adele Rowley, Director, Pharmacology, Cellzome
>
>
> Who should attend Neurodegenerative Disorders 2004 ?
>
> *> Heads of Clinical Research, CNS
> *> Heads of Clinical Development/ VP Clinical Development
> *> Heads of R&D (Pain/CNS/Depression)
> *> Heads of CNS therapeutics
> *> Global Brand Area, CNS
> *> Heads of Pre-Clinical Development, CNS
> *> CNS Clinical Project Management
> *> Heads of Neuroscience Research
> *> Business Development Executives
> *> Directors of Strategic Planning and Development
> *> Chief Medical Officers
> *> Chief Scientific Officers
> *> Research Scientists
>
> Also included in this 2 day conference is an interactive pre-conference workshop,
> a more intimate working environment, ideal for networking opportunities:
>
> Surrogate Markers in Central Nervous System Drug Development
> Workshop Leader: Professor Tonmoy Sharma, Clinical Neuroscience Research Centre
> Tuesday 30th March 2004
>
> - PRICING -
> Attend the:
> 2 Day conference with interactive workshop - ONLY GBP1400 plus VAT(17.5%)
> 2 Day conference - ONLY GBP1099 plus VAT(17.5%)
> Workshop only - ONLY GBP650 plus VAT(17.5%)
>
> - BOOKINGS -
> Booking is easy, simply contact Lorraine Lescure on:
> Telephone: +44 (0)20 8767 6711
> Fax: +44 (0)20 8767 5001
> Email: lorraine.lescure{}visiongain.com
> Terms and conditions apply - see below.
>
> Please find below the conference agenda. To book your place at
> Neurodegenerative Disorders 2004 simply give me a quick ring or email
> stating whether you require a single place or a group booking.
>
> I look forward to hearing from you soon.
>
> Regards
>
> Lorraine Lescure
> Account Manager
> Visiongain b2b Conferences
> Tel: +44 (0) 20 8767 6711
> mailto:lorraine.lescure~!~visiongain.com
>
>
>
> Pre Conference workshop -
> Surrogate Markers in Central Nervous System Drug Development
>
> Tuesday 30th March 2004
> Workshop Leader: Professor Tonmoy Sharma
> Clinical Neuroscience Research Centre
>
> Examine the relationship between brain and behaviour using a>
> variety of surrogate makers:
>
> *> Use of Cognitive Function
> *> Startle Response
> *> Eye Movements
> *> Critical Flicker Fusion
> *> Evoked Potential
> *> Electronic Data Capture
>
>
> Full conference agenda
>
> Day One
>
> Wednesday 31st March 2004
>
>
> Conference Chairperson
> Dr. Donna Barten
> Senior Research Investigator, Neuroscience Drug Discovery
> Bristol-Myers Squibb
>
> 9:00 Registration and coffee
>
> 9:30 Opening remarks from the Chair
>
> INTRODUCTION TO NEURODEGENERATIVE DISORDERS
>
> 9:45 How to Identify Novel Molecular Targets for
>
> Neurodegenerative Disorders?
> *> Pathologic insight to disease targets
> *> Identifying genes, SNPs and proteomic analysis
> *> What are the pathways to novel targets?
> *> End game of target validation
>
> Dr. Beth Hoffman
> Head Neuroscience Discovery Research
> Eli Lilly
>
> 10:20 What are the Issues in the Development of Drugs for Neurodegenerative Disorders?
>
> *> Importance of safety assessment
> *> What is the proof of concept?
> *> Advantages and disadvantages of human models
> *> Biomarkers/ surrogate markers
> *> Can we avoid lengthy patient studies?
> *> What about the placebo affect?
>
> Dr. Christian Gilles
> Director, R&D & Head, CNS Ageing Research
> Forenap
>
> 11:00 Morning Coffee
>
> ALZHEIMER'S DISEASE
>
> 11:20 Causes of Alzheimer> '> s Disease and Treatment Options
>
> *> Aetiology of disease
> *> Current treatment options
> *> Amyloid hypothesis of AD
> -Secretase Inhibitors
> -Immunotherapy
> -Aggregation Inhibitors
> *> Secretase Inhibitors
> *> Targeting tau in AD
>
> Dr. Hans Basun
> Senior Clinical Research Physician
> AstraZeneca
>
> 12:00 Use of Secretase Inhibitors in Animal Models of AD
>
> *> What are the characteristics of secretase inhibitors?
> *> Comparison of transgenic mice with Alzheimer's disease
> *> Tg2576 and YAC-APP transgenic mice
> *> Guinea pig models
> *> Transgenic rat models
>
> Dr. Donna Barten
> Senior Research Investigator
> Neuroscience Drug Discovery
> Bristol-Myers Squibb
>
> 12:40 Lunch
>
> 14:00 CASE STUDY: Will Axura be the First Drug for Treating
> Moderate-to-Severe Alzheimers?
>
> The only drugs approved for Alzheimer's disease are indicated for
> mild-to-moderate patients. Number of major pharma companies are
> currently developing therapies for moderate-to-severe indications.
> Axura entered the European Market in 2003 and set to enter the
> US in 2004.
>
> *> What are the sales expectations and reasons why?
> *> First Alzheimer's drug to be indicated for moderate-to-severe
> patients
> *> Advantages: Merz estimates the drug could delay the need to
> transfer patients to long-term care and reduce level of care
> required by over 50 hours a month
>
> Friedhelm Klingenburg
> Senior VP for Corporate Development
> Merz Pharmaceuticals
>
> 14:40 Cellzome's Alzheimer's Disease Drug Discovery Programme
>
> *> What is the major focus of Alzheimer> '> s Disease drug discovery
> programmes?
> - inhibition of amyloid formation
>
> *> Cellzome> '> s approach: proteomics technology
> - Tandem Affinity Purification procedure
> - LC/MS-MS protein mass spectrometry capabilities
>
> *> Analysis: over 200 molecular associations in APP processing and
> novel interaction of regulatory and modulatory importance
> identified
>
> Adele Rowley
> Director, Pharmacology
> Cellzome
>
> 15:20 Afternoon Tea
>
> AMYOTROPHIC LATERAL SCLEROSIS
>
> 15:40 CASE STUDY: Rilutek, The only Drug Approved for Treating
> Amyotrophic Lateral Sclerosis
>
> *> ALS : a good model for the development in the degenerative
> disease
> - lesson from rilutek
>
> *> Only approved drug for treatment of ALS by the FDA
> *> How does it work?
> *> Development and potential in the new indications
>
> Dr. Michel Dib
> Medical Director for Internal Medicines Department
> Aventis
>
> 16:20 CASE STUDY: Phase III results of Neurodex for Treating
> Pseudobulbar Affect
>
> *> What is pseudobulbar affect?
> - seen in numerous neurodegenerative disease
>
> *> Neurodex technology overview>
>
> *> Clinical and regulatory development status
> - first half of phase III studies completed with ALS patients
> - second half of phase III studies in progress with MS patients
>
> Dr. Gerald Yakatan
> President and CEO
> Avanir Pharmaceuticals
>
> 17:00 Questions and Discussion
>
>
> Day Two Thursday 1st April 2004
>
> 09:00 Coffee
>
> 09:30 Opening Remarks from the Chair
>
> PARKINSON'S DISEASE
>
> 09:45 CASE STUDY: Leading Therapy for PD, Mirapex by Boehringer
> Ingelheim and Pharmacia
>
> Dopamine agonists entered the market in the 1980's- PD market was
> worth $1.2 billion in 2002 with 60% of its value coming from the
> sale of dopamine agonists.
>
> *> Parkinson's disease market profile: levodopa, dopamine agonists
> and COMT inhibitors
> *> Mirapex had 17% of market share in 2002- What are the reasons
> for its success?
> *> Research showing slower rate of decline in dopaminergic neuronal
> functioning in patients receiving Mirapex to those treated with
> levodopa
> *> Implications
>
> Dr. Chriso Babatsikos
> International Product Manager Pramipexole
> Boehringer-Ingelheim
>
> 10:20 CASE STUDY: Surgical Interventions- Activa Parkinson's
> Control Therapy by Medtronic
>
> *> Implantation Procedure
> *> How does it work?- counteraction of dyskinetic movements
> *> FDA approval for expanded use
> *> What is the future of the surgical interventions market for PD?
>
> Pino Carbone
> Business Manager - Activa Therapy
> Medtronic Europe
>
> 11:00 Morning Coffee
>
> 11:20 Is Gene Therapy a Viable Option for Treating PD?
>
> ProSavin is being developed by Oxford BioMedica, which utilises the
> company's proprietary lentivirus and involves the transfer of the
> tyrosine hydroxylase gene with a dopamine turnover inhibiting gene.
> *> What are the requirements for molecular genetic analysis?
> *> How to deliver genes to the nervous system?
> *> Targets and models
> *> Update on the clinical development of ProSavin
> *> What are neuro-protective approaches for Parkinson's disease?
>
> Prof. Alan Kingsman
> Chief Executive Officer
> Oxford BioMedica
>
> 12:00 Can Brain Stem Cell Transplantation be used for CNS Repair?
>
> *> What are the advantages?
> *> What risks are present?
> *> Transplant strategies
> *> Graft effects in animal models of neurodegnerative disease:
> functional and structural integration
> *> What are the mechanisms of graft activity?
> *> Prospects for clinical applications
>
> Dr. Helen Hodges
> Head of Functional Assessment Group
> ReNeuron
>
> 12:40 Lunch
>
> 14:00 Opening Remarks from the Chair
>
> MULTIPLE SCLEROSIS
>
> 14:10 CASE STUDY: Antegren, A Novel Approach to MS Treatment
> by Elan
>
> *> Results of Antegren clinical trials for relapsing MS
> *> Different mechanism of action from any other approved MS drug
> *> Advantages of Antegren?
>
> Dr. Stephen Donoghue
> VP of Clinical Development, Europe
> Elan
>
> 14:50 Therapeutic Plasma Exchange (TPE) for MS and other CNS
> Demyelinating Diseases
>
> *> TPE: evidence of efficacy in CNS demyelinating diseases
> *> What are the clinical factors predictive of response to TPE?
> *> What are the pathological factors involved in response to TPE?
> *> Theories of mechanisms of action
>
> Dr. Mark Keegan
> Consultant
> Department of Neurology
> Mayo Clinic and Foundation
>
> 15:30 Afternoon Tea
>
> HUNTINGTON'S DISEASE
>
> 15:50 How can the Immune System be Harnessed for Attenuating
> Neurodegeneration?
> *> Autoimmunity is a beneficial physiological response to CNS trauma
> *> What are the safe ways to induce a protective immune response?
> *> Incubated macrophages in spinal cord injury - Phase I clinical study
> *> Therapueatic vaccination for neurodegenerative disorders - PN277
>
> Dr. Eti Yole
> Vice President Product Research and Development
> Proneuron Biotechnologies>
>
> 16:30 The Feasibility of Using Synthetic DNA Oligonucleotides to
> Prevent Htt Aggregation in Huntington's Disease
>
> *> Is synthetic DNA an effective therapeutic agent for many disease
> indications?
> *> Functions as an anti-sense molecule, RNAi , a gene correction
> agent and perhaps an apatamer
> *> Toxicity studies and immunogenic responses
> *> What is the potential of using short modified oligonucleotides to
> disrupt the process of aggregate formation in Huntington's
> Disease?
>
> Eric Kmiec
> Chief Scientific Officer
> NaPro Bio Therapeutics
>
> 17:00 Questions and Discussion
>
> 17:20 Chairman Summation
>
> 17:30 Close of Conference
>
>
>
>
>
>
>
>
> Terms & Conditions
> NB - Due to high demand, we do not 'reserve' or 'hold' places - a request for an invoice to be raised will be treated as an official booking and will be subject to the cancellation policy as outlined below.
> Cancellations/substitutions and name changes: All bookings carry a 50% liability after the booking has been made, by post fax, email or web. There will be no refunds for cancellations received on or after one month before the start of the conference (e.g. cancellation on or after 20th January for a conference starting on 20th February). If you decide to cancel after this date the full invoice remains payable. Conference notes, which are available on the day, will be sent to you. Unfortunately we are not able to transfer places between conferences and executive briefings. However if you are unable to attend the event you may make a substitution/name change at any time as long as we are informed in writing by e-mail, fax or post. Name changes and substitutions must be from the same company and are not transferable between companies or countries.
>
> Indemnity: visiongain Ltd reserve the right to change the conference/executive briefing content, timing, speakers or venue without notice. The event may be postponed or cancelled due to acts of terrorism, war, extreme weather conditions, industrial action, acts of God or any event beyond the control of visiongain Ltd. If such a situation arises we will endeavour to reschedule the event. However, visiongain Ltd cannot be held responsible for any cost, damage or expenses, which may be incurred by the customer as a consequence of the event being postponed or cancelled. We therefore strongly advise all customers to take out insurance to cover the cost of the registration, travel and expenses.
> To unsubscribe please reply with unsubscribe in the subject line.
>
> Data protection: Visiongain Ltd gathers and manages data in accordance with the Data Protection Act 1998. Information contained about you may be used to update you on visiongain Ltd products and services via post, telephone, fax or email, unless you state otherwise. We may share your data with external companies offering complimentary products or services. If you wish your details to be amended, suppressed or not passed onto any external third party, please send your request to the Database Manager, visiongain Ltd, 40 Tooting High Street, London, SW17 0RG. Alternatively, you can visit our website www.visiongain.com <http://www.visiongain.com/> and amend your details. Please allow approximately 30 days for your removal or update request, you may receive additional pieces of communication from visiongain Ltd during the transitional period, whilst the changes come into effect.
>
>
#####################################################################################

This email has been scanned by MailMarshal, an email content filter.

#####################################################################################
Received on 2004-02-19 - 12:40 GMT